Literature DB >> 31171311

Disease activity assessment in patients with psoriatic arthritis.

Andreas Kerschbaumer1, Josef S Smolen1, Daniel Aletaha2.   

Abstract

Psoriatic arthritis (PsA) is an inflammatory disease in patients with a personal or family history of psoriasis. While synovitis is the major hallmark, enthesitis, dactylitis, axial inflammation, and skin and nail involvement are variable in prevalence and severity. The assessment of disease activity is important to determine the treatment target ("Treat-to-Target") as well as early response to therapy, because a prolonged ineffective medication may not only be associated with an adverse disease outcome but constitutes a waste of individual and/or societal expenses. Various measures of disease activity have been established for all manifestations individually ('uni-dimensional approach') or by combining such measures into a single umbrella score ('multi-dimensional approach'). Because pathogeneses and therapeutic responsiveness differ among individual domains, a uni-dimensional approach is preferred. The major uni-dimensional index is the Disease Activity index for PSoriatic Arthritis, which provides a continuous scale and allows calculating disease activity at any point in time, determining response to therapy and defining disease activity states, such as remission, as a treatment target. The assessment of the various domains by individual and combined indices is discussed.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  DAPSA; Disease activity; MDA; Psoriatic arthritis; Treat-to-target; Treatment response

Mesh:

Year:  2018        PMID: 31171311     DOI: 10.1016/j.berh.2018.08.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  3 in total

Review 1.  Disease activity indices in psoriatic arthritis: current and evolving concepts.

Authors:  Chrysoula G Gialouri; George E Fragoulis
Journal:  Clin Rheumatol       Date:  2021-05-18       Impact factor: 2.980

2.  Effect of high-intensity exercise on cardiorespiratory fitness, cardiovascular disease risk and disease activity in patients with inflammatory joint disease: protocol for the ExeHeart randomised controlled trial.

Authors:  Kristine Røren Nordén; Hanne Dagfinrud; Anne Grete Semb; Jonny Hisdal; Kirsten K Viktil; Joseph Sexton; Camilla Fongen; Jon Skandsen; Thalita Blanck; George S Metsios; Anne Therese Tveter
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

3.  Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis.

Authors:  Laura C Coates; Josef S Smolen; Philip J Mease; M Elaine Husni; Joseph F Merola; Eric Lespessailles; Mitsumasa Kishimoto; Lisa Macpherson; Andrew J Bradley; Rebecca Bolce; Philip S Helliwell
Journal:  RMD Open       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.